These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hemolytic uremic syndrome in children. Talarico V; Aloe M; Monzani A; Miniero R; Bona G Minerva Pediatr; 2016 Dec; 68(6):441-455. PubMed ID: 27768015 [TBL] [Abstract][Full Text] [Related]
3. The Role of the Complement System in the Pathogenesis of Infectious Forms of Hemolytic Uremic Syndrome. Avdonin PP; Blinova MS; Generalova GA; Emirova KM; Avdonin PV Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38254639 [TBL] [Abstract][Full Text] [Related]
4. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases. Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409 [TBL] [Abstract][Full Text] [Related]
5. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Khalid M; Andreoli S Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336 [TBL] [Abstract][Full Text] [Related]
6. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Walsh PR; Johnson S Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046 [TBL] [Abstract][Full Text] [Related]
7. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297 [TBL] [Abstract][Full Text] [Related]
8. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence. Mahat U; Matar RB; Rotz SJ Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658 [TBL] [Abstract][Full Text] [Related]
10. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Westra D; Volokhina EB; van der Molen RG; van der Velden TJ; Jeronimus-Klaasen A; Goertz J; Gracchi V; Dorresteijn EM; Bouts AH; Keijzer-Veen MG; van Wijk JA; Bakker JA; Roos A; van den Heuvel LP; van de Kar NC Pediatr Nephrol; 2017 Feb; 32(2):297-309. PubMed ID: 27718086 [TBL] [Abstract][Full Text] [Related]
11. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Mannucci PM; Cugno M Thromb Res; 2015 Nov; 136(5):851-4. PubMed ID: 26386489 [TBL] [Abstract][Full Text] [Related]
12. Atypical reduction of plasma ADAMTS13 activity by a non-IgG-type inhibitor in a patient with hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli. Nakayama S; Hirashio S; Yorishima H; Doi T; Yoshida Y; Matsumoto M; Masaki T CEN Case Rep; 2019 Nov; 8(4):266-270. PubMed ID: 31177384 [TBL] [Abstract][Full Text] [Related]
14. Hemolytic Uremic Syndrome and Kidney Transplantation: A Case Series and Review of the Literature. Milan Manani S; Virzì GM; Giuliani A; Clementi A; Brocca A; Dissegna D; Martino F; d''Amore ESG; Ronco C Nephron; 2017; 136(3):245-253. PubMed ID: 28419995 [TBL] [Abstract][Full Text] [Related]
15. An Unusual Case of Clostridium Difficile Colitis and Hemolytic Uremic Syndrome in a Teenager. Dasgupta K; Santos A; McCaul K S D Med; 2019 Jul; 72(7):294-297. PubMed ID: 31461583 [TBL] [Abstract][Full Text] [Related]
16. Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Buelli S; Zoja C; Remuzzi G; Morigi M Microorganisms; 2019 Jan; 7(1):. PubMed ID: 30634669 [TBL] [Abstract][Full Text] [Related]
17. Haemolytic uraemic syndrome associated with non shiga toxin-producing Escherichia coli bacteraemia: a case report. Bally S; Fourcade J; Frémeaux-Bacchi V BMC Nephrol; 2019 May; 20(1):157. PubMed ID: 31064333 [TBL] [Abstract][Full Text] [Related]